Some really sad news to report here, as Syracuse basketball sophomore forward Robert Braswell will not suit up again for the rest of the 2019-20 campaign.
Syracuse basketball’s roster for the duration of the 2019-20 term just got a bit thinner, with the Orange announcing Sunday via its Twitter account that Robert Braswell is done in the current stanza because of pain in his shins.
Here’s the full statement from the ‘Cuse. “Due to pain in his lower legs that makes it physically unable for him to compete, Syracuse sophomore Robert Braswell will not play for the rest of the season.”
From myself and every other member of Orange Nation, we’re wishing you a speedy recovery, Robert! The 6-foot-7 Braswell, an athletic forward who can also shoot the ball quite well from 3-point land, has seen action in seven of Syracuse’s 14 affairs so far in 2019-20, according to his bio published on ESPN.com.
Up until now, he had averaged 6.9 minutes per contest, along with 1.7 points and 1.1 rebounds, while connecting on 44.4 percent from the field and 66.7 percent from beyond the arc.
Mike Waters of Syracuse.com reported on Sunday that Braswell is “a candidate to seek a medical redshirt,” since he has played in less than 30 percent of the Orange’s regular-season encounters.
After the ‘Cuse bested in-state foe Niagara on Dec. 28, head coach Jim Boeheim said that it could help Braswell to take the rest of 2019-20 off, because of the constant pain in his shins. As such, while totally disappointing, it’s not all that surprising Braswell will not suit up any longer in the present campaign.
Injuries and other developments have certainly diminished Syracuse’s depth. Freshman center John Bol Ajak elected to redshirt. Sophomore point guard Jalen Carey had surgery on his right thumb. Freshman combo guard Brycen Goodine broke his nose during a practice session last week. And freshman center Jesse Edwards sprained his ankle a couple of weeks ago.
Coming into 2019-20, the Orange thought it possessed a full cadre of scholarship players. Today, Boeheim’s options are noticeably fewer.